Anti CD319 Antibody: Key Insights and Benefits for Researchers

The anti-CD319 antibody from Alpha Lifetech Incorporation is a cutting-edge research tool designed to aid in the study of various cellular processes and diseases. This high-quality antibody specifically targets CD319, also known as SLAMF7, a crucial surface marker found on multiple immune cell types, including activated B cells and plasma cells, By leveraging the unique properties of this antibody, researchers can effectively investigate the roles of CD319 in immune responses, cancer, and autoimmune disorders. The antibody is validated for multiple applications, including flow cytometry, immunohistochemistry, and Western blotting, ensuring its versatility in various experimental setups, Alpha Lifetech Incorporation is committed to providing reliable, innovative solutions that advance scientific research. The anti-CD319 antibody embodies this mission, empowering scientists to uncover new insights into the immune system and develop novel therapeutic strategies. Experience the impact of high-quality reagents with Alpha Lifetech—the trusted partner in your research endeavors

Hot Selling Product

ADT1745-Human Anti-CD3ExCD20 Bispecific Antibody

ADT1746-Human Anti-CD3ExBCMA Bispecific Antibody

ADT1748-Human Anti-IGF1RxHer3 Bispecific Antibody

ADT1749-Human Anti-CD3ExCD20 Bispecific Antibody

ADT1752-Human Anti-CD3xCEACAM5 Bispecific Antibody

The Clear Choice of anti CD319 antibody Pioneers in the Field From Concept to Delivery

In the ever-evolving field of biochemistry and therapeutic development, the need for reliable and effective antibodies is paramount. At Alpha Lifetech Inc., we pride ourselves on being pioneers in the realm of anti-CD319 antibody production. Our journey from concept to delivery is marked by rigorous research and a steadfast commitment to quality, driven by a team of seasoned scientists with a wealth of experience in membrane protein production, Nanobody discovery, and monoclonal antibody development. Our dedication to understanding the complexities of molecular interactions has enabled us to create nearly 10,000 high-quality reagents, including drug target antibodies and cytokines. Choosing Alpha Lifetech means partnering with a trusted leader who offers not just products, but also expertise and support throughout your research and development processes. Our anti-CD319 antibodies are meticulously developed to ensure specificity and efficacy, positioning them as the clear choice for global buyers seeking reliable solutions for their projects. By maintaining stringent quality control and rigorous validation procedures, we deliver exceptional performance in various applications, from therapeutic discovery to diagnostics. Join us on this innovative journey and discover how our products can enhance your research outcomes.

The Clear Choice of anti CD319 antibody Pioneers in the Field From Concept to Delivery

Category	Measurement	Details	Outcome
Target Antigen	CD319	A unique marker for B-cell differentiation	High specificity
Development Stage	Preclinical	Validated in vitro and in vivo	Promising early results
Application	Therapeutic	Potential for treating B-cell malignancies	Positive therapeutic index
Production Method	Recombinant	Utilizes mammalian cell culture	High yield and purity
Regulatory Status	Pending	Undergoing regulatory review	Expected approval timeline: 2024
Market Potential	High	Growing demand for B-cell therapeutics	Estimated worth: $500 million

Emerging Trends in Anti-CD319 Antibody Research and Development

This chart illustrates the increasing trend of research publications related to anti-CD319 antibodies from 2018 to 2023. The data signifies a notable rise in scientific interest and investment in the development of anti-CD319 antibodies over these years. It is evident that as more researchers engage in this field, the potential applications of these antibodies in therapeutic treatments are being recognized. The surge in publications from just 5 in 2018 to a staggering 70 in 2023 indicates a growing recognition of the importance of CD319 as a target in immunotherapy and cancer treatment strategies. This focus not only highlights the advancements in antibody research but also reflects the broader implications of CD319 in clinical applications, fostering hope for improved patient outcomes in the future.